GlassScriptPhysician profile
Michael Gregory Foss
NPI 1285193193
$25,440.43
in general payments reported to CMS, 2019-2025
27 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.50 · 2022: $268 · 2023: $2,797 · 2024: $1,866 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $7,642 · Travel and Lodging: $1,549 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,789.00 |
| Food and Beverage | $7,641.91 |
| Travel and Lodging | $1,549.02 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $18,257.29 | 2024-2025 | |
| Amgen INC. | $961.25 | 2022-2025 | Otezla, Otezla |
| Abbvie INC. | $823.02 | 2023-2025 | |
| Galderma Laboratories, L.P. | $682.57 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $677.35 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $521.35 | 2023-2024 | Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $414.99 | 2023-2025 | Dupixent |
| Dermavant Sciences, INC. | $389.82 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $372.89 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $341.69 | 2023-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $290.29 | 2023 | |
| Lilly USA, LLC | $276.68 | 2021-2024 | Olumiant, Taltz |
| Journey Medical Corporation | $248.67 | 2023 | |
| Ucb, INC. | $205.05 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $164.35 | 2023 | Sotyktu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $153.26 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Genzyme Corporation | $96.48 | 2023-2025 | |
| Mimedx Group, INC. | $67.28 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.07 | 2023 | Spevigo |
| Incyte Corporation | $41.81 | 2023 | Opzelura |
| Merz North America, INC. | $35.71 | 2024 | |
| Cipher Pharmaceuticals US LLC | $31.72 | 2025 | Spinosad, Natroba |
| Arcutis Biotherapeutics, INC. | $22.95 | 2025 | Zoryve |
| Strata Skin Sciences, INC. | $22.94 | 2025 | Xtrac |
| Almirall LLC | $21.62 | 2023 | Klisyri |
| Biofrontera INC. | $20.69 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $7.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Foss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.